Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship-Reference-Cited by-同舟云学术

Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship

Published:2024-08-08 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Casadevall Arturo¹^ORCID,Focosi Daniele²,Pirofski Liise-anne³,Shoham Shmuel⁴

Affiliation:

1. Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health , Baltimore, Maryland , USA

2. North-Western Tuscany Blood Bank, Pisa University Hospital , Pisa , Italy

3. Divison of Infectious Diseases, Albert Einstein College of Medicine , Bronx, New York , USA

4. Division of Infectious Diseases, Johns Hopkins School of Medicine , Baltimore, Maryland , USA

Abstract

Abstract The COVID-19 pandemic witnessed the greatest deployment of monoclonal antibody (mAb) therapies for an infectious disease, but all were defeated by SARS-CoV-2 evolution. As new mAbs are developed, the infectious disease community needs stewardship practices to reduce emergence of resistance.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae408/58971169/ciae408.pdf

Reference30 articles.

1. Prevalence of immunosuppression among US adults;Martinson;JAMA,2024

2. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2;Focosi;Clin Microbiol Infect,2024

3. COVID-19 update: an EUA for pemivibart (Pemgarda) for pre-exposure prophylaxis;Med Lett Drugs Therapeut,2024

4. Coronavirus resistance database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons;Tzou;PLoS One,2022

5. Emergence of SARS-CoV-2 escape mutations during bamlanivimab therapy in a phase II randomized clinical trial;Choudhary;Nat Microbiol,2022